Cogent Biosciences Inc
COGT
NASDAQ
Biotechnology
$37.93
USD
+0.62 (+1.66%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $6.51B
Volume 1.2M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-377.18M
TTM
-32.8%
YoY
Operating Cash Flow
$-307.55M
TTM
-31.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 13.4 | 14.4 | 23.9 | 28.2 | 31.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 75.6 | 83.4 | 99.5 | 103.6 | 102.6 |
Operating Income | -75.6 | -83.4 | -99.5 | -103.6 | -102.6 |
EBITDA | -74.9 | -82.7 | -98.9 | -103.0 | -101.9 |
Other Income / Expense | -0.0 | -0.0 | -7.2 | -0.1 | -0.0 |
Total Other Income / Expense | 2.1 | 2.4 | -3.0 | 6.3 | 6.2 |
Income Before Income Taxes | -73.5 | -80.9 | -102.5 | -97.4 | -96.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -73.5 | -80.9 | -102.5 | -97.4 | -96.4 |
Consolidated Net Income / Loss | -73.5 | -80.9 | -102.5 | -97.4 | -96.4 |
Net Income Attributable to Common Shareholders | -60.9 | -69.0 | -88.4 | -86.0 | -88.9 |
Basic EPS | -$0.53 | -$0.50 | -$0.59 | -$0.53 | -$0.52 |
Diluted EPS | -$0.53 | -$0.50 | -$0.59 | -$0.53 | -$0.52 |
Basic Shares Outstanding | 114.5M | 137.6M | 150.3M | 162.2M | 171.0M |
Diluted Shares Outstanding | 114.5M | 137.6M | 150.3M | 162.2M | 171.0M |